Major vaccine policy changes could be on the horizon as the HHS removes key advisors. Click for my thoughts on what this may ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...

HHS Secretary Robert F. Kennedy Jr. abruptly removed 17 vaccine experts from the CDC’s Advisory Committee on Immunization ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Although it appears not to cause more severe illness, preliminary data demonstrate that the variant exhibits significant ...

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.